KOL Perspectives: Novel treatment options for moderate UC

KOL Perspectives: Novel treatment options for moderate UC


  • Products Id :- GDHC052SP
  • |
  • Pages: 27
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

KOL Perspectives: Novel treatment options for moderate UC

Summary

This KOL Insight briefing focuses on KOLs views of novel treatment options for moderate UC.

The briefing includes analysis of KOL opinion on the following topic areas-

- Current clinical management of moderate UC patients

- Awareness of novel therapies in development suitable for moderate UC

- Perception of Phase II apremilast data in moderate UC

- Expectations for treatment algorithm positioning of apremilast

- Potential for future combination therapy with apremilast

- Perception of apremilast's other labels in psoriasis (PsO) and psoriatic arthritis (PsA)

Key Highlights

- Nearly half of all UC patients seen in the majority of KOLs' clinical practices are considered as having moderate UC

- Most KOLs would initially treat moderate UC patients with 5-ASAs, moving to anti-TNF therapies if patients do not respond

- KOLs stated that less than 10% of moderate UC patients required surgical intervention.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our inflammatory bowel disease key opinion leaders (KOLs)

- In total, we conducted interviews with 10 KOLs: 5 Europe-based & 5 N. America-based

- Interviews performed during March 2018

- KOL data is analyzed to produce: Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts.

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on "novel treatment options for moderate UC"

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of UC

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Celgene

UC, apremilast, comorbidities

select a license
Single User License
USD 2500 INR 172400
Site License
USD 5000 INR 344800
Corporate User License
USD 7500 INR 517200

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com